Frequently Asked Questions for Somatic Cell Genome Editing FOAs
We appreciate your interest in the Somatic Cell Genome Editing funding opportunities and hope that you and your team will choose to submit an application. This list of frequently asked questions will be updated periodically as new questions from potential applicants are received.
(Note an earlier version of this answer incorrectly stated that RM-18-012, RM-18-013 and RM-18-018 did not allow foreign components.)
- RFA-RM-18-012: $225,000 in FY18; $450,000 per year FY19-22
- RFA-RM-18-013: $500,000 per year FY18-22
- RFA-RM-18-015: $390,000 per year FY18-22
- RFA-RM-18-016: $500,000 per year FY18-20 (UG3); $1M per year FY21-22 (UH3)
- RFA-RM-18-017: $250,000 per year FY18-FY22
- RFA-RM-18-018: $1.25M in FY19; $3.25M per year FY20-22; $1.0M in FY23
The funding announcements state that there will be data sharing among the consortium members and to the public through the DCC. Will my institution be able to protect its intellectual property developed through these cooperative agreements?
I’m interested in using genome editing to treat disease X. Can I propose the use of a disease-specific animal model as proof of concept studies in my application? Or do I have to use the reporter animals generated in the Consortium?
For RFA-RM-18-016, can you propose to subcontract any large animal studies in the UH3 phase with a collaborating center? If so, would I need a fully executed subcontract agreement in place, or is it sufficient to submit a signed letter of collaboration with a budget from the proposed large animal site?
... For the UH3 phase, NIH expects that the testing of genome editing delivery vehicles in large animals will be carried out in a future SCGE Large Animal Testing Center. However, investigators should include a budget for large animal testing (including the purchase of animals, per diem, and costs of animal procedures) from a source other than the SCGE Large Animal Testing Center, due to the possibility that the SCGE animal resources may be unavailable or inadequate for testing the delivery technology. If the SCGE Large Animal Testing Center is available at the time of the UH3 transition, NIH will decrease the award by the amount budgeted for large animal testing.
Questions Generated from the Applicant Informational Webinar:
- Liver (cell types other than hepatocytes)
- Nervous System
- Cardiovascular System, including hematopoietic and immune cells
- Sensory Organs
Applications proposing delivery ex vivo will have a lower priority; in vivo is preferred. However, if the technology could do both, that is considered responsive.
- Greater capacity and versatility regarding the size and type of genome editing machinery delivered
- Reduced immunogenicity
- Avoidance of pre-existing immunity
- Improved or expanded cell-type targeting
- Simplification or increased scalability of production
- Less invasive mode of administration
- Support of transient or regulatable expression of genome editors
This page last reviewed on March 23, 2018